Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro.

Related Articles

Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro.

Artif Cells Nanomed Biotechnol. 2017 Nov 27;:1-11

Authors: Ganassin R, Merker C, Rodrigues MC, Guimarães NF, Sodré CSC, Ferreira QDS, da Silva SW, Ombredane AS, Joanitti GA, Py-Daniel KR, Zhang J, Jiang CS, de Morais PC, Mosiniewicz-Szablewska E, Suchocki P, Longo JPF, Meijer J, Estrela-Lopis I, de Azevedo RB, Muehlmann LA

Abstract
Nanocapsules (NCS-DOX) with an oily core of selol and a shell of poly(methyl vinyl ether-co-maleic anhydride) covalently conjugated to doxorubicin were developed. These nanocapsules are spherical, with an average hydrodynamic diameter of about 170 nm, and with negative zeta potential. NCS-DOX effectively co-delivered the selol and the doxorubicin into 4T1 cells and changed the intracellular distribution of DOX from the nuclei to the mitochondria. Moreover, a significantly increased cytotoxicity against 4T1 cells was observed, which is suggestive of additive or synergic effect of selol and doxorubicin. In conclusion, PVM/MA nanocapsules are suitable platforms to co-deliver drugs into cancer cells.

PMID: 29179603 [PubMed - as supplied by publisher]

from #PM All via ola Kala on Inoreader http://ift.tt/2BmfiGw